PDS Biotechnology Corp reports results for the quarter ended September 30 - Earnings Summary

PDS Biotechnology

13/11/2026 15:22

PDS Biotechnology Corp PDSB.OQ reported a quarterly adjusted loss of 11 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -19 cents.  The mean expectation of two analysts for the quarter was for a loss of 10 cents per share. Wall Street expected results to range from -11 cents to -10 cents per share.
Reported revenue was zero​; analysts expected zero. 
PDS Biotechnology Corp's reported EPS for the quarter was a loss of 11 cents​.
The company reported a quarterly loss of $7.62 million.
PDS Biotechnology Corp shares had risen by 30.5% this quarter and gained 27.3% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 4.5% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for PDS Biotechnology Corp is $4.50, about 78.2% above its last closing price of $0.98
This summary was machine generated from LSEG data November 13 at 03:22 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Sep. 30 2026 
-0.10
-0.11
Missed
Jun. 30 2026 
-0.13
-0.18
Missed
Mar. 31 2026 
-0.15
-0.13
Beat
Dec. 31 2025 
-0.19
-0.15
Beat